Literature DB >> 22947303

Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models.

Dasha Fuentes1, Lewis Chacón, Angel Casacó, Nuris Ledón, Nidia Fernández, Arianna Iglesias, Diana R Hernández, Belinda Sánchez, Rolando Pérez.   

Abstract

Anti-epidermal growth factor receptor (EGFR) therapies have been proven clinically effective for a variety of epithelial tumours. Vaccination of mice with the extracellular domain (ECD) of autologous EGFR overcomes the tolerance to self-EGFR and has antimetastatic effect on EGFR+ tumour. Because EGF/EGFR-signalling plays an important role in the inflammation stage of wound healing, the main objective of this study was to explore the possible role of murine (m) EGFR-ECD vaccine in the croton-oil-induced ear oedema and wound healing process in mice as autologous experimental models, mimicking the possible post-surgical wound complication in patients treated with human EGFR-ECD/VSSP vaccine. Mice were intramuscularly immunised four times; biweekly with the mEGFR-ECD/VSSP/Mont. Seven days later, an 8 mm diameter, full-thickness skin wound was created on the back of each animal. Immunisation induced a strong specific humoral response against the mEGFR-ECD protein and a DTH dose-response curve but interestingly, animals treated with mEGFR-ECD/VSSP/Mont had similar inflammatory and healing speed responses compared to control ones. These data suggest that application of mEGFR-ECD/VSSP vaccine as a therapeutic approach in cancer patients could not elicit a poor healing process after surgery.
© 2012 The Authors. International Wound Journal © 2012 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  Autologous animal model; Cancer vaccine; Epithelial tumours; Immunotherapy

Mesh:

Substances:

Year:  2012        PMID: 22947303      PMCID: PMC7950343          DOI: 10.1111/j.1742-481X.2012.01074.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  35 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease.

Authors:  Gryssell Rodriguez; Gisela Gonzalez; Tania Crombet; Agustin Lage
Journal:  Expert Rev Respir Med       Date:  2011-06       Impact factor: 3.772

3.  Effect of an EGF-cancer vaccine on wound healing and inflammation models.

Authors:  A Casacó; Y Díaz; N Ledón; N Merino; O Vadés; G Garcia; B Garcia; G González; R Pérez
Journal:  J Surg Res       Date:  2004-11       Impact factor: 2.192

Review 4.  The type 1 (EGFR-related) family of growth factor receptors and their ligands.

Authors:  S A Prigent; N R Lemoine
Journal:  Prog Growth Factor Res       Date:  1992

5.  Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine.

Authors:  Belinda Sánchez Ramírez; Yeranddy Aguiar Alpízar; Diana Rosa Hernández Fernández; Greta Garrido Hidalgo; Ailem Rabasa Capote; Rolando Pérez Rodríguez; Luis Enrique Fernández
Journal:  Vaccine       Date:  2008-07-29       Impact factor: 3.641

6.  Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor.

Authors:  L Raaberg; E Nexø; P E Jørgensen; S S Poulsen; M Jakab
Journal:  Pediatr Res       Date:  1995-02       Impact factor: 3.756

7.  Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas.

Authors:  W J Gullick; J J Marsden; N Whittle; B Ward; L Bobrow; M D Waterfield
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

8.  Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.

Authors:  A Osio; C Mateus; J-C Soria; C Massard; D Malka; V Boige; B Besse; C Robert
Journal:  Br J Dermatol       Date:  2009-04-10       Impact factor: 9.302

9.  Inflammation of guinea pig dermis. Effects of leukotriene B4 receptor antagonist, SC-41930.

Authors:  D J Fretland; D L Widomski; J M Zemaitis; R E Walsh; S Levin; S W Djuric; R L Shone; B S Tsai; T S Gaginella
Journal:  Inflammation       Date:  1990-12       Impact factor: 4.092

10.  Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing.

Authors:  S Tokumaru; S Higashiyama; T Endo; T Nakagawa; J I Miyagawa; K Yamamori; Y Hanakawa; H Ohmoto; K Yoshino; Y Shirakata; Y Matsuzawa; K Hashimoto; N Taniguchi
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

View more
  2 in total

1.  Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies.

Authors:  Narjara González Suárez; Gretchen Bergado Báez; Mabel Cruz Rodríguez; Amelia Gutiérrez Pérez; Lisset Chao García; Diana Rosa Hernández Fernández; Judith Raymond Pous; Belinda Sánchez Ramírez
Journal:  Oncotarget       Date:  2017-08-03

2.  Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.

Authors:  Iraida Caballero; Lazaro E Aira; Anabel Lavastida; Xitlally Popa; Javier Rivero; Joaquín González; Mónica Mesa; Narjara González; Kelly Coba; Patricia Lorenzo-Luaces; Barbara Wilkinson; Yuliannis Santiesteban; Yanela Santiesteban; Mayelin Troche; Eduardo Suarez; Tania Crombet; Belinda Sánchez; Angel Casacó; Amparo Macías; Zaima Mazorra
Journal:  Front Pharmacol       Date:  2017-05-10       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.